| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.4 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.4 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |